Serwis Infona wykorzystuje pliki cookies (ciasteczka). Są to wartości tekstowe, zapamiętywane przez przeglądarkę na urządzeniu użytkownika. Nasz serwis ma dostęp do tych wartości oraz wykorzystuje je do zapamiętania danych dotyczących użytkownika, takich jak np. ustawienia (typu widok ekranu, wybór języka interfejsu), zapamiętanie zalogowania. Korzystanie z serwisu Infona oznacza zgodę na zapis informacji i ich wykorzystanie dla celów korzytania z serwisu. Więcej informacji można znaleźć w Polityce prywatności oraz Regulaminie serwisu. Zamknięcie tego okienka potwierdza zapoznanie się z informacją o plikach cookies, akceptację polityki prywatności i regulaminu oraz sposobu wykorzystywania plików cookies w serwisie. Możesz zmienić ustawienia obsługi cookies w swojej przeglądarce.
Currently, there are various approaches for developing therapeutic vaccines for chronic hepatitis B patients. Previously, an antigen–antibody-based therapeutic vaccine (YIC) has been conducted in a double-blind placebo controlled phase IIb clinical trial in 242 chronic hepatitis B patients. At the end of follow-up for 24 weeks, HBeAg sero-conversion rate was 21.6% in the 60μg immunized group, compared...
This study is aimed to investigate if there was increased risk of HBV acquisition among first graders in Taiwan during a 3-year follow-up period.A total of 1545 healthy first graders, who were vaccinated against HBV in infancy, were recruited in 2005. All subjects were checked for hepatitis B surface antigens (HBsAg), antibodies to HBsAg (anti-HBs), and to the hepatitis B core antigen (anti-HBc)....
To investigate the humoral immune response to measles, rubella, and varicella-zoster virus (VZV) vaccines in biliary atresia (BA) children before liver transplantation, we conducted the cross-sectional designed study. Fifty BA children (age, 3.6±0.2 years; 24 girls) who had not yet received liver transplantation, and another 150 healthy controls (age, 4.0±0.1 years; 78 girls) were recruited into this...
To study the responses of chronic hepatitis B patients to yeast-derived HBsAg-HBIG complexes (YIC) and the mechanisms involved, twenty HBeAg-positive chronic hepatitis B patients were immunized with 60μg of YIC or alum as the control at 4-week intervals, for 24 weeks. Five of ten patients responded to 60μg YIC immunization showing ≥2 logs decrease of serum HBV DNA with loss or marked reduction of...
A therapeutic vaccine for viral hepatitis B composed of yeast-derived recombinant HBsAg complexed to human anti-HBs immunoglobulin (yeast-derived-immunogenic complex, YIC) with alum as the adjuvant was evaluated for safety. In stage 1, 22 healthy Chinese adult volunteers were vaccinated with three doses of 30μg, 60μg or 90μg of HBsAg in YIC at 4-week intervals. In stage 2, nine volunteers received...
SARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID 5.0 of the live virus 10 3.6 to 10 4.6 times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation...
Podaj zakres dat dla filtrowania wyświetlonych wyników. Możesz podać datę początkową, końcową lub obie daty. Daty możesz wpisać ręcznie lub wybrać za pomocą kalendarza.